The GHC summit at Harvard, is a yearly event designed to catalyze collaborations to eliminate...
There are no announcements yet.
May 2018, the Cannabis Science team participated in the 2018 Global Health Catalyst Summit held at Harvard Medical School in Boston, MA. The Global Health Catalyst (GHC) summit at Harvard, is a premier yearly event designed to catalyze high impact international collaborations to eliminate global health disparities, with main focus on cancer and related diseases. During this summit Mr. Raymond C. Dabney, the Company’s President, Chief Executive Officer (CEO), and Co-founder was named the recipient of the esteemed 2018 Harvard Global Health Catalyst (GHC) Industry Leader Award and was the keynote speaker during the Phytomedicines Session.
The theme of the Phytomedicines Session was From Farm to Bedside: Advancing Clinical Translation of Medical Cannabis and Other Phytomedicines for Global Health. Mr. Dabney discussed the development of effective cannabinoids and the creation of the Cannabis Science Global Consortium, a research and development framework and platform to cooperate and collaborate with stakeholders worldwide.
Cannabis Science’s Chief Medical Officer (CMO), Dr. Allen Herman, moderated the Phytomedicines Session and also presented on the role of cannabinoids in reducing the pain therapeutic divide between developed and developing countries, and CBIS’ research and development plan.
Pan African Ambassador for Food Security and member of the Cannabis Science Scientific Advisory Board, Dr. Brylyne Chitsunge, discussed opportunities to cultivate, extract, manufacture, package, and distribute cannabinoids in Sub-Saharan Africa along with the task of educating the rest of the continent through actions and success. The Ambassador’s main take away for the audience was the emphasis of the importance of micro-nutrition and food security within the overall approach to improve healthcare outcomes throughout all of Africa.
GHC Europe 2018
Cannabis Science participated in the Europe Global Health Catalyst (GHC) Summit and Summer Workshop in Germany, organized by at the University of Heidelberg and Harvard Medical School’s Global Health Catalyst. CBIS’ Scientific Advisory Board Member and Chief Executive Officer (CEO) of Elpasso Farms in South Africa, Dr. Brylyne Chitsunge, was invited to deliver a keynote address on engaging the African Diaspora, phytomedicines in global health, and closing the cancer pain divide. This two-day event held August 30th and 31st, is a pre-summit to the annual GHC Summit at Harvard Medical School in Boston, Massachusetts, and was attended by government officials, private-sector leaders, and researchers from Europe, the United States, and throughout Africa.
As keynote speaker, Dr. Chitsunge also discussed Elpasso Farms’ and Cannabis Science’s initiatives in Africa in the areas of food security, collaborations, and economic development. The economic development initiatives presented include education, drug development, and job creation.
Cannabis Science and Elpasso Farms have recently entered into an agreement to develop a phytomedicines initiative in South Africa. This partnership will include establishing research, development, cultivation, testing, manufacturing, and production facilities. Additionally, CBIS and Elpasso intend to establish the Pan-African Agriculture and Commerce University (PAACU), which will serve as a platform for research, drug development, education, and training throughout Africa.
Additionally, Cannabis Science, Elpasso Farms, and Harvard Medical School’s GHC recently announced the signing of a historic collaboration agreement to develop initiatives throughout
April 2017, the Cannabis Science team participated in the 2017 Global Health Catalyst Summit held at Harvard Medical School in Boston, MA. Mr. Dabney was the keynote speaker and panelist for a special session on “Cannabis Science Versus Cancer and Other Malignancies”.
Mr. Dabney discussed how cannabinoids can be used to treat cancer and other diseases, manage the side effects of cancer treatment like radiotherapy and chemotherapy, and potential applications of medical cannabis in global health to close the global pain divide; Cannabis Science’s vision for the global health and development impact of cannabinoid-based medicines; and the need for greater public education on the importance of medical cannabis research.
Additionally, Mr. Dabney presented summit participants with an overview of the company's drug development program, as well as with an update on Cannabis Science's Collaborative Research Agreement (CRA) with Dana-Farber Cancer Institute (Dana-Farber). Dr. Allen Herman, Chief Medical Officer (CMO) of CBIS, Inc. Co-Chaired this session and participated in the discussion on the epidemiology of cancer and the utilization of opioids in Africa, which reflects the pain divide. Mr. Dabney and Dr. Herman lead CBIS’ collaboration with DFCI.
Good morning Everyone!
Wishing everyone the Best!
It sounds like we need some clarity, it seems enough shareholders are asking if they get “ENDO”...Good morning Everyone!
Wishing everyone the Best!
It sounds like we need some clarity, it seems enough shareholders are asking if they get “ENDO” stock symbol shares for the Cannabis Science share exchange.
We are not issuing “ENDO” stock symbol shares for the exchange.
Everyone will be receiving a new class of OMNI/Thermic shares just for Cannabis Science to trade on Cannabis Science merits with a brand new symbol.
*** This is exactly why we put out the Berkshire News Release explaining successful conglomerate structures:
*** Each OMNI/Thermic subsidiary company of merit will have its own trading symbol, all under the Parent Company OMNI/Thermic.
The Parent Company trades off the merits of ALL its subsidiaries, hence Berkshire is trading at $300.000.00 USD per share based on all its subsidiary’s values combined.
Each subsidiary/owned by the Company trades with its own stock symbol on its own merits or they have no symbol at all.
*** Example: Wells Fargo Bank owned by Berkshire: $36.00 USD per share, trading on its own merits.
*** Please understand OUR structure will be similar to Berkshire in this way:
1. OMNICANNA will create several new classes of shares to accommodate its subsidiaries and registering them to get the new trading symbols each one different from “ENDO”.
2. Each Company will be filed to trade under a new symbol, not “ENDO” stock symbol.
3. The ENDO stock symbol is for the Parent Company, OMNICANNA similar to Berkshire trading at $300,000.00 USD per share based on the values of ALL their subsidiaries trading or not, we could only be so fortunate. We are certainly moving in that direction for our wealth and happiness.
We are creating new classes of shares and new trading symbols for each company of merit all under OMNICANNA, the parent company.
*** When the smoke clears:
All with separate trading symbols and owned by the parent OMNICANNA (soon to be Thermic Sciences):
OMNICANNA OTC: ENDO (The Parent Company will trade based on the merits of ALL its subsidiaries combined, like Berkshire, we could only be this fortunate)
Cannabis Science: OTC: OMNI. Class A (this one will be for Cannabis Science share exchange only, until the new symbol is approved)
Thermic Power: OTC: OMNI. Class B (we will dividend shares to OMNICANNA shareholders to make the shareholder base to call up a new symbol to trade)
Thermic Heating: OTC: OMNI. Class C (we will dividend shares to OMNICANNA shareholders to make the shareholder base to call up a new symbol to trade)
Hempery et al: OTC: OMNI. Class E (we will dividend shares to OMNICANNA shareholders to make the shareholder base to call up a new symbol to trade)
*** When we get here or anywhere near it, ALL our OMNI/Thermic shareholders will own everyone one of the new trading classes through dividends and have 3-4-5 different public companies in their asset portfolio all coming from the one Company OMNI/Thermic trading under “ENDO”. This is how we are creating some serious wealth for all our shareholders
Omnicanna soon to be Thermic Sciences, trading under OTC: ENDO we anticipate the trading price will catch up and trade based on the combined merits and values of all its trading or non-trading subsidiary companies.
Hope this helps, we are moving much stronger, step by step.
We will make an announcement shortly on closing out the Cannabis Science FR and continue progressing forward with our aggressive growth schedule. On track and on the path.
Stay Strong and Stay Safe.
All the Best.
Raymond Show more